+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 15 Actively Recruiting clinical trials

P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the consistency of immune responses to three different batches of an investigational chickenpox vaccine called VNS vaccine in healthy children aged 12 to 15 months who have not had chickenpox or received a chickenpox vaccine before. The study also compares the safety and immune response of the VNS vaccine to an approved chickenpox vaccine known as Varivax. This Phase 3a study is sponsored by GlaxoSmithKline and aims to better understand the immune protection provided by these vaccines. Participants are randomly assigned to receive one dose of either one of the three investigational VNS vaccine lots or one of two lots of the marketed Varivax vaccine. Along with the chickenpox vaccine, they also receive one dose each of measles, mumps, and rubella MMR vaccine, hepatitis A vaccine HAV, and a pneumococcal conjugate vaccine PCV which could be PCV 13, Vaxneuvance, or PCV 20 depending on availability and country recommendations. All vaccines are given on Day 1 of the study. During the study, researchers monitor the participants immune responses by measuring antibodies against varicella zoster virus VZV and other vaccine components at Day 43. They also track safety by recording any side effects or adverse events from Day 1 to Day 181. The study includes diary reports by parents and regular clinical evaluations to assess immune response and safety outcomes. Participation involves a single vaccination visit and follow-up assessments over approximately six months.

Age: 12Months - 15MonthsAll GendersPhase 3
97 locations
R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of elismetrep, compared with placebo, for treating moderate to severe migraine in adults. This randomized, double-blind, multicenter outpatient study focuses on patients aged 18 to 75 who experience frequent migraine attacks. The trial aims to better understand elismetreps impact on migraine symptoms and relief. Participants are randomly assigned to receive a single oral dose of either elismetrep 10 mg, elismetrep 20 mg, or placebo. The study is conducted in a parallel design with triple masking to reduce bias. The primary focus is on pain freedom and relief from the most bothersome migraine symptoms within two hours after dosing. During the trial, participants will report their migraine symptoms and responses to treatment using study questionnaires and an electronic diary. Researchers will assess outcomes such as pain relief at 2 hours, sustained pain freedom up to 48 hours, freedom from nausea, photophobia, and phonophobia, and the need for rescue medication. Safety is monitored through adverse event reporting up to 8 days post-dose. The study is expected to last until December 2027.

Age: 18Years - 75YearsAll GendersPhase 3
72 locations
E

Actively Recruiting

Researchers are evaluating GB-0895 as an add-on therapy for adolescents and adults with severe asthma that remains uncontrolled despite using inhaled corticosteroids and other asthma controllers. This global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study aims to assess the effectiveness and safety of GB-0895 in improving asthma outcomes. Participants will receive either GB-0895 or a placebo through subcutaneous injections every six months during the treatment period. The study includes a screening and run-in phase from weeks -5 to 0, a treatment phase lasting 52 weeks, and a follow-up phase lasting from week 52 to week 90. An optional open-label extension allows continued GB-0895 treatment from week 52 through week 142. During the study, participants will undergo various assessments including lung function tests, questionnaires about asthma symptoms and quality of life, and monitoring for asthma exacerbations and adverse events. Researchers will measure outcomes such as the annual rate of asthma exacerbations and changes in lung function over 52 weeks. Safety evaluations will continue throughout treatment and follow-up. The total participation duration may extend up to nearly three years if the optional extension is chosen.

Age: 12Years - 80YearsAll GendersPhase 3
158 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and tolerability of a new multivalent pneumococcal vaccine called PG4 in healthy infants. The study compares this new vaccine to the currently used 20-valent pneumococcal conjugate vaccine 20vPnC to see how well they protect against infections like pneumonia, meningitis, and ear infections caused by Streptococcus pneumoniae. The trial is a Phase 3, randomized, double-blinded study involving about 2400 infants around 2 months old. Participants will be randomly assigned to receive either the new PG4 vaccine or the 20vPnC vaccine. Both vaccines are given as injections into the left thigh muscle at 2, 4, 6, and between 12 to 15 months of age. The study lasts about 16 to 19 months, during which infants will have six clinic visits and one phone call to monitor their health and any side effects. During these visits, parents or legal guardians will report any local reactions, systemic events, or other adverse effects experienced by the infant after each vaccine dose. Researchers will track events occurring within seven days after each dose, as well as serious adverse events up to six months following the last dose. The goal is to understand the safety profile of the new vaccine compared to the existing one over the course of the study period.

Age: 42Days - 98DaysAll GendersPhase 3
78 locations
S

Actively Recruiting

Researchers are investigating the effects and safety of the medicine PF-07275315 for treating moderate to severe Chronic Obstructive Pulmonary Disease COPD, a lung condition that makes breathing difficult and impacts daily life. This interventional study involves adults aged 35 to 80 who have had COPD for at least 12 months and experienced at least two moderate or severe exacerbations in the past year while on stable maintenance treatment. Participants will receive either PF-07275315 or a placebo through multiple subcutaneous injections at the clinic. The Phase 2 portion lasts 24 weeks with study involvement totaling about 40 weeks and includes 11 clinic visits. The Phase 3 portion lasts 52 weeks with approximately 68 weeks total involvement and 18 clinic visits. The study compares outcomes between those receiving PF-07275315 and those receiving placebo to evaluate safety and effectiveness. During the study, participants will undergo regular assessments including lung function tests such as forced expiratory volume FEV1, monitoring of exacerbation rates, symptom questionnaires, safety lab tests, electrocardiograms, and vital signs. Safety and adverse events will be closely tracked throughout the study, and participants will be followed for the full duration of their assigned phase to monitor changes and outcomes related to COPD.

Age: 35Years - 80YearsAll GendersPhase 2Phase 3
189 locations
E

Actively Recruiting

Researchers are evaluating depemokimab as a treatment for adults aged 40 to 80 years with moderate to severe chronic obstructive pulmonary disease COPD characterized by type 2 inflammation and frequent exacerbations. This Phase 3 trial aims to assess the efficacy and safety of depemokimab when added to standard care compared to a placebo with standard care. The study is sponsored by GlaxoSmithKline and focuses on reducing the rate of moderate to severe COPD exacerbations. Participants will receive either subcutaneous injections of depemokimab or placebo alongside their optimized inhaler therapies, which include inhaled corticosteroids, long-acting muscarinic antagonists, and long-acting beta2-adrenergic agonists, all maintained for at least six months prior to the study. The study uses a randomized, double-blind, parallel-group design and lasts for up to 104 weeks, during which participants continue their standard care while receiving the study treatments. Throughout the study, participants will be regularly monitored for COPD exacerbations and changes in respiratory symptoms using validated tools like the St. Georges Respiratory Questionnaire and the Evaluating Respiratory Symptoms in COPD score. Researchers will also track emergency visits or hospitalizations related to exacerbations. Safety assessments and efficacy measurements will be collected throughout the two-year period to evaluate the impact of depemokimab as an add-on treatment.

Age: 40Years - 80YearsAll GendersPhase 3
193 locations
E

Actively Recruiting

Researchers are evaluating whether weekly treatment with semaglutide, a glucagon-like peptide-1 receptor GLP-1R agonist, can reduce illicit opioid use among adults receiving outpatient treatment for opioid use disorder. This phase 2 trial focuses on participants who are already on buprenorphine or methadone maintenance therapy. The study aims to compare semaglutide against a placebo to see if it increases the chances of abstaining from illicit and nonprescribed opioids. Participants will be randomly assigned to receive either semaglutide or a placebo injection once a week for 12 weeks. The semaglutide dose starts at 0.25 mg and is gradually increased to a maximum of 1.0 mg weekly, depending on tolerance. After the treatment period, there is a one-week washout phase followed by a final follow-up about four weeks later. The study uses subcutaneous injections administered via an injection pen in an outpatient setting. Throughout the trial, participants will visit the clinic weekly for urine drug screenings, pregnancy tests, vital sign checks, and to complete questionnaires about mental health and drug use. They will also complete smartphone surveys at scheduled times. Blood samples will be collected twice during the study, and a physical exam and medical history will be recorded at the start. Researchers will monitor abstinence from opioids weekly and track opioid cravings and stimulant use through questionnaires, with the total study duration lasting approximately 19 weeks.

Age: 18Years - 75YearsAll GendersPhase 2
4 locations
O

Actively Recruiting

Researchers are conducting a global, multi-center observational trial to study patients with recurrent symptomatic paroxysmal or persistent atrial fibrillation AF. The trial evaluates the PulseSelect PFA System, a market-approved device used for pulmonary vein isolation, to better understand its safety and effectiveness over a 36-month period. This study follows patients who have not responded well to at least one Class I or III antiarrhythmic drug. Participants will undergo an ablation procedure using the PulseSelect PFA System according to standard hospital care. The study observes two groups based on AF type paroxysmal and persistent. After treatment, patients will be followed with scheduled visits at 3, 6, 12, 24, and 36 months, including 24-hour Holter heart monitoring at the 6, 12, 24, and 36 month visits. During the study, participants will have regular assessments to track heart rhythm and safety outcomes. Researchers will measure freedom from atrial fibrillation at 36 months after ablation and monitor for device- or procedure-related adverse events up to 6 months. The total participant involvement spans three years, providing long-term data on treatment outcomes and safety.

Age: 18Years +All Genders
23 locations
C

Actively Recruiting

Researchers are evaluating two different methods of pacing the heart to treat heart failure. The study compares the current standard method, Cardiac Resynchronization Therapy CRT, which involves implanting a pacing lead on the surface of the left lower chamber of the heart, with a newer method called Left Bundle Branch Area Pacing LBBAP, where a lead is implanted in the Left Bundle Branch Area of the heart. This study aims to assess the safety and effectiveness of these two pacing approaches in people with heart failure. Participants will be randomly assigned to one of two groups. One group will receive a BSC CRT-D device with a quadripolar left ventricular lead, while the other will receive a BSC CRT-D device with an INGEVITY pacesense lead implanted in the Left Bundle Branch Area. Both devices include a right atrial lead and a defibrillation lead. The device will be programmed according to the assigned group. The study will monitor participants for up to five years to evaluate outcomes. During the study, participants will be monitored through remote patient monitoring with the LATITUDE NXT system and will attend follow-up visits as required by the study protocol. Researchers will collect data on outcomes such as mortality, heart transplant, heart failure events, device therapy for ventricular arrhythmias, and system-related complications. The primary outcome includes a composite measure of these events over up to five years, and system complication rates will be assessed at 12 months. Participants are expected to remain in the study for the full duration of follow-up and comply with all study requirements.

Age: 18Years +All GendersPhase Not Applicable
43 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety, performance, and functional outcomes of the Indigo Aspiration System for treating pulmonary embolism PE. This observational study focuses on patients with acute PE and aims to gather real-world data on how well the device works and its safety over time. Participants receive frontline treatment with the Indigo Aspiration System as part of their standard care for acute PE. The study monitors patients for safety events within 48 hours after the procedure and assesses heart function by measuring the right ventricle to left ventricle ratio. Quality of life and functional outcomes are evaluated at 90 days, along with longer-term monitoring for serious device-related events and mortality up to one year and 30 days respectively. During the study, participants will undergo diagnostic imaging and clinical assessments to track their recovery and the effects of the device. Researchers will collect data on adverse events, quality of life questionnaires, exercise capacity tests, and symptom scales. The total participation lasts up to several months, including follow-up visits to ensure comprehensive monitoring of safety and function after treatment.

Age: 18Years +All Genders
79 locations

1-10 of 15

1